Haemoseal Spray for Nonvariceal Gastrointestinal Bleeding: An Initial Experience from India

 

 Permissions and Reprints

ABSTRACT

Background and Aims: The aim was to reflect the use and effectiveness of Haemoseal spray as a treatment option in gastrointestinal (GI) bleed in everyday gastroenterology practice. Materials and Methods: This was a single‑center, retrospective observational study conducted over a period of 12 months from January 2016 to December 2016. Consecutive patients of upper or lower GI bleed where haemoseal powder was used either as salvage therapy after a failed hemostasis or as an add‑on to the standard methods or as monotherapy were identified and analyzed. Results: Of 284 patients with GI bleed, haemoseal spray was used in 20 (7.04%) patients. Bleeding was due to duodenal ulcer in 7 (35%), gastric ulcer 3 (15%), esophageal ulcer 2 (10%), colonic postpolypectomy bleed 2 (10%), gastric carcinoma 2 (10%), Mallory‑Weiss tear 1 (5%), postsphincterotomy bleed 1 (5%), gastric antral vascular ectasia 1 (5%), and portal hypertensive gastropathy 1 (5%). The nature of bleed was oozing in 17 (85%) and spurting in 3 (15%). Initial hemostasis when used as monotherapy was seen in 3/3, as add‑on therapy in 6/6, and as salvage therapy in 9/11 patients. Rebleed was seen in 4 (20%) and 30‑day mortality was seen in 2 (10%) patients. Rebleed rate at day 7 was more in monotherapy cases; however, the difference was not statistically significant (33.33% vs. 16.66% vs. 18.18%, P = 0.819). Conclusion: Haemoseal spray is an effective hemostatic agent in various clinical situations with GI bleeding, especially when used as salvage therapy or as add‑on therapy.

• REFERENCES

• 1 Sung JJ, Luo D, Wu JC, Ching JY, Chan FK, Lau JY. et al. Early clinical experience of the safety and effectiveness of hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43: 291-5
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Smith LA, Stanley A, Morris J. Hem spray for non-variceal upper gastrointestinal bleeding: Results of the SEAL dataset (survey to evaluate the application of hemospray in the luminal tract). Gut 2012; 62: A61-2
  Google Scholar
• 3 Moosavi S, Barkun A. Case series: Utility of hemospray in management of benign upper and lower GI bleed of various etiologies: Preliminary experience. Can J Gastroenterol 2012; 26: A081
  Google Scholar
• 4 Soulellis CA, Carpentier S, Chen YI, Fallone CA, Barkun AN. Lower GI hemorrhage controlled with endoscopically applied TC-325 (with videos). Gastrointest Endosc 2013; 77: 504-7
  CrossrefPubMedGoogle Scholar
• 5 Holster IL, Brullet E, Kuipers EJ, Campo R, Fernández-Atutxa A, Tjwa ET. et al. Hemospray treatment is effective for lower gastrointestinal bleeding. Endoscopy 2014; 46: 75-8
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Cox ED, Schreiber MA, McManus J, Wade CE, Holcomb JB. New hemostatic agents in the combat setting. Transfusion 2009; 49 Suppl 5 248S-5520
  CrossrefPubMedGoogle Scholar
• 7 Holster IL, De Maat MP, Ducharme R, Kuipers EJ, Tjwa ET. In vivo examination of the effects of the hemostatic powder (HemosprayTM) on coagulation and thrombus formation inhumans. Gastrointest Endosc 2012; 75: AB240
  CrossrefGoogle Scholar
• 8 Haemoseal Powder Device. Product Manual. Available from: http://www.shailiendoscopy.com/Heamoseal-powder-device.pdf [Last accessed 2018 Jan 31].
  Google Scholar
• 9 Bustamante-Balén M, Plume G. Hemostatic powders for gastrointestinal bleeding. World J Gastrointest Pathophysiol 2014; 5: 284-92
  CrossrefPubMedGoogle Scholar
• 10 Chen YI, Barkun A, Nolan S. Hemostatic powder TC-325 in the management of upper and lower gastrointestinal bleeding: A two-year experience at a single institution. Endoscopy 2015; 47: 167-71
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Smith LA, Stanley AJ, Bergman JJ, Kiesslich R, Hoffman A, Tjwa ET. et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: Results of the survey to evaluate the application of hemospray in the luminal tract. J Clin Gastroenterol 2014; 48: e89-92
  CrossrefPubMedGoogle Scholar
• 12 Babiuc RD, Purcarea M, Sadagurschi R, Negreanu L. Use of hemospray in the treatment of patients with acute UGIB – Short review. J Med Life 2013; 6: 117-9
  PubMedGoogle Scholar
• 13 Sulz MC, Frei R, Meyenberger C, Bauerfeind P, Semadeni GM, Gubler C. et al. Routine use of hemospray for gastrointestinal bleeding: Prospective two-center experience in Switzerland. Endoscopy 2014; 46: 619-24
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Moosavi S, Chen YI, Barkun AN. TC-325 application leading to transient obstruction of a post-sphincterotomy biliary orifice. Endoscopy 2013; 45 Suppl 2 E130
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Beg S, Al-Bakir I, Bhuva M, Patel J, Fullard M, Leahy A. et al. Early clinical experience of the safety and efficacy of endoClot in the management of non-variceal upper gastrointestinal bleeding. Endosc Int Open 2015; 3: E605-9
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Chen YI, Barkun AN, Soulellis C, Mayrand S, Ghali P. Use of the endoscopically applied hemostatic powder TC-325 in cancer-related upper GI hemorrhage: Preliminary experience (with video). Gastrointest Endosc 2012; 75: 1278-81
  CrossrefPubMedGoogle Scholar
• 17 Leblanc S, Vienne A, Dhooge M, Coriat R, Chaussade S, Prat F. et al. Early experience with a novel hemostatic powder used to treat upper GI bleeding related to malignancies or after therapeutic interventions (with videos). Gastrointest Endosc 2013; 78: 169-75
  CrossrefPubMedGoogle Scholar